[go: up one dir, main page]

RU2013138721A - Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови - Google Patents

Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови Download PDF

Info

Publication number
RU2013138721A
RU2013138721A RU2013138721/15A RU2013138721A RU2013138721A RU 2013138721 A RU2013138721 A RU 2013138721A RU 2013138721/15 A RU2013138721/15 A RU 2013138721/15A RU 2013138721 A RU2013138721 A RU 2013138721A RU 2013138721 A RU2013138721 A RU 2013138721A
Authority
RU
Russia
Prior art keywords
sepsis
thrombopenia
predicting
risk
kits
Prior art date
Application number
RU2013138721/15A
Other languages
English (en)
Other versions
RU2589903C2 (ru
Inventor
Филип ЛАССАЛЬ
Original Assignee
Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)
Юниверсите Де Друа Э Де Ла Санте Лилль 2
Сантр Оспиталье Режьональ Юниверситер Де Лилль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль), Юниверсите Де Друа Э Де Ла Санте Лилль 2, Сантр Оспиталье Режьональ Юниверситер Де Лилль filed Critical Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)
Publication of RU2013138721A publication Critical patent/RU2013138721A/ru
Application granted granted Critical
Publication of RU2589903C2 publication Critical patent/RU2589903C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Способ прогнозирования риска развития органной недостаточности, выбранной из группы, состоящей из дыхательной недостаточности, почечной недостаточности и тромбопении у пациента, страдающего сепсисом, включающий этап, состоящий в измерении концентрации эндокана в образце крови, полученном от указанного пациента, страдающего сепсисом.

Claims (1)

  1. Способ прогнозирования риска развития органной недостаточности, выбранной из группы, состоящей из дыхательной недостаточности, почечной недостаточности и тромбопении у пациента, страдающего сепсисом, включающий этап, состоящий в измерении концентрации эндокана в образце крови, полученном от указанного пациента, страдающего сепсисом.
RU2013138721/15A 2011-01-21 2012-01-20 Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови RU2589903C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11151656.3 2011-01-21
EP11151656 2011-01-21
EP11306293.9 2011-10-06
EP11306293 2011-10-06
PCT/EP2012/050844 WO2012098219A1 (en) 2011-01-21 2012-01-20 Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood

Publications (2)

Publication Number Publication Date
RU2013138721A true RU2013138721A (ru) 2015-02-27
RU2589903C2 RU2589903C2 (ru) 2016-07-10

Family

ID=45498005

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013138721/15A RU2589903C2 (ru) 2011-01-21 2012-01-20 Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови

Country Status (10)

Country Link
US (1) US9945873B2 (ru)
EP (1) EP2666019B1 (ru)
JP (1) JP2014503076A (ru)
KR (1) KR20140018249A (ru)
CN (1) CN103477229B (ru)
CA (1) CA2826033A1 (ru)
ES (1) ES2899007T3 (ru)
RU (1) RU2589903C2 (ru)
SG (2) SG192593A1 (ru)
WO (1) WO2012098219A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101410417B1 (ko) 2013-01-30 2014-07-03 경북대학교 산학협력단 혈액내의 엔도칸 측정 방법
CA2903929A1 (en) 2013-03-04 2014-09-12 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
EP3440467B1 (en) 2016-04-08 2020-05-13 Lunginnov Method for diagnosing postoperative pulmonary infections in patients who underwent surgery
EP3279665B1 (en) 2016-08-04 2020-07-08 Roche Diagniostics GmbH Circulating esm-1 (endocan) in the assessment of atrial fibrillation
KR102193393B1 (ko) * 2019-05-29 2020-12-21 경희대학교 산학협력단 신부전 환자에서 신장 이식 거부반응 및 심혈관계 합병증의 진단 또는 예측을 위한 마커로써 엔도칸 및 이의 용도
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
CN116097099A (zh) 2020-08-14 2023-05-09 豪夫迈·罗氏有限公司 用于评定无症状脑梗死和认知衰退的esm-1
CN112162098A (zh) * 2020-08-17 2021-01-01 中国人民解放军陆军军医大学第二附属医院 一组血清差异蛋白在制备用于检测人ⅱ型血小板减少症试剂中的应用
US20240230676A1 (en) * 2021-04-30 2024-07-11 Roche Diagnostics Operations, Inc. Esm1 marker panels for early detection of sepsis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6670328B1 (en) * 1997-06-24 2003-12-30 Institut Pasteur De Lille Proteins and peptides derived from protein ESM-1 and their uses in the treatment and diagnosis of diseases linked to leukocyte migration
EP1175615A2 (en) * 1999-04-02 2002-01-30 Icos Corporation Lfa-1 regulatory binding site and uses thereof
FR2816410B1 (fr) * 2000-11-09 2003-04-18 Pasteur Institut Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
AT504943A1 (de) * 2007-03-12 2008-09-15 Biomedica Medizinprodukte Gmbh Diagnose septischer komplikationen
WO2010040538A1 (en) * 2008-10-08 2010-04-15 Inserm (Institut National De La Santé Et De La Recherche Medicale) Marker peptides for determining the occurrence of an inflammatory state in a subject
EP2350646B1 (en) * 2008-10-28 2016-01-13 Assistance Publique - Hôpitaux de Paris Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock

Also Published As

Publication number Publication date
SG192593A1 (en) 2013-09-30
SG10201600502XA (en) 2016-02-26
US9945873B2 (en) 2018-04-17
EP2666019A1 (en) 2013-11-27
ES2899007T3 (es) 2022-03-09
WO2012098219A1 (en) 2012-07-26
US20140017707A1 (en) 2014-01-16
CN103477229B (zh) 2016-02-03
CN103477229A (zh) 2013-12-25
RU2589903C2 (ru) 2016-07-10
JP2014503076A (ja) 2014-02-06
AU2012208532A1 (en) 2013-08-15
CA2826033A1 (en) 2012-07-26
KR20140018249A (ko) 2014-02-12
EP2666019B1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
RU2013138721A (ru) Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови
PH12014500650A1 (en) Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage
EA201391245A1 (ru) Интеррогативные клеточные анализы и их применение
EA201690465A1 (ru) Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
EP2061907A4 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
EA201390413A1 (ru) Применение миелоидных клеток в качестве биомаркеров в диагностике рака
HK1202157A1 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
IN2013MN01890A (ru)
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
CY1117838T1 (el) Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112015014232A2 (pt) lesão renal aguda
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
EP4509835A3 (en) Utility of protein in the prediction of in vivo effects
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
WO2013167727A3 (en) Method for determining arthritis relapse risk
WO2015006657A8 (en) Method for the diagnosis and prognosis of cancer
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
JP2015528562A5 (ru)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190121